---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-009898"
form_type: "8-K"
ticker: "PAVM"
cik: "0001624326"
company_name: "PAVmed Inc."
filed_at: "2024-03-14T23:59:59+00:00"
generated_at: "2026-06-04T19:38:29.772370+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# PAVmed subsidiary Lucid Diagnostics raises $12.5M via Series B Preferred Stock offering and exchange

## Summary
- Lucid Diagnostics sold 12,495 shares of Series B Convertible Preferred at $1,000/share, raising $12.495M.
- Investors exchanged 13,625 Series A and 10,670 Series A-1 shares for 31,790 Series B shares.
- Closing on March 13, 2024; Lucid filed certificate of designation for Series B and amendment for Series A-1.
- Registration rights agreement filed for resale of common stock issuable upon conversion of Series B Preferred.

## SEC filing metadata
- accession: 0001493152-24-009898
- form_type: 8-K
- ticker: PAVM
- cik: 0001624326
- company_name: PAVmed Inc.
- filed_at: 2024-03-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1624326/000149315224009898/0001493152-24-009898-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1624326/000149315224009898/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-009898
- JSON: https://secwatch.observer/filing/0001493152-24-009898.json
- Plain text: https://secwatch.observer/filing/0001493152-24-009898.txt

## Key facts
- Material Agreements
  PAVmed Inc. entered into Registration Rights Agreement with Series B Investors (effective 2024-03-13).
  - Action: entry
  - Counterparty: Series B Investors
  - Effective: 2024-03-13
  source text: Lucid Diagnostics and the Series B Investors also executed a registration rights agreement (the “ Registration Rights Agreement ”), pursuant to which the Company agreed to file a registration statement covering the resale of the shares of Common Stock issuable pursuant to the Series B Preferred Stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1624326/000149315224009898/0001493152-24-009898-index.htm
- Material Agreements
  PAVmed Inc. entered into Series B Subscription Agreement with certain accredited investors valued at 12,495 shares of Lucid Diagnostics’ newly designated Series B Convertible Preferred Stock, par value (effective 2024-03-13).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain accredited investors
  - Value: 12,495 shares of Lucid Diagnostics’ newly designated Series B Convertible Preferred Stock, par value
  - Effective: 2024-03-13
  source text: On March 13, 2024, Lucid Diagnostics Inc. (the “ Lucid Diagnostics ”), a majority owned subsidiary of PAVmed Inc. (the “ Company ”), entered into subscription agreements (each, a “ Series B Subscription Agreement ”) and exchange agreements (each, an “ Exchange Agreement ”) with certain accredited investors (collectively, the “ Series B Investors ”), which agreements provided for (i) the sale to the Series B Investors of 12,495 shares of Lucid Diagnostics’ newly designated Series B Convertible Preferred Stock, par value $0.001 per share (the “ Series B Preferred Stock ”), at a purchase price of $1,000 per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1624326/000149315224009898/0001493152-24-009898-index.htm
- Material Agreements
  PAVmed Inc. entered into Exchange Agreement with certain accredited investors valued at 13,625 shares of Lucid Diagnostics’ Series A Convertible Preferred Stock, par value $0.001 per share (effective 2024-03-13).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain accredited investors
  - Value: 13,625 shares of Lucid Diagnostics’ Series A Convertible Preferred Stock, par value $0.001 per share
  - Effective: 2024-03-13
  source text: On March 13, 2024, Lucid Diagnostics Inc. (the “ Lucid Diagnostics ”), a majority owned subsidiary of PAVmed Inc. (the “ Company ”), entered into subscription agreements (each, a “ Series B Subscription Agreement ”) and exchange agreements (each, an “ Exchange Agreement ”) with certain accredited investors (collectively, the “ Series B Investors ”), which agreements provided for (i) the sale to the Series B Investors of 12,495 shares of Lucid Diagnostics’ newly designated Series B Convertible Preferred Stock, par value $0.001 per share (the “ Series B Preferred Stock ”), at a purchase price of $1,000 per share, and (ii) the exchange by the Series B Investors of 13,625 shares of Lucid Diagnostics’ Series A Convertible Preferred Stock, par value $0.001 per share (the “ Series A Preferred Stock ”), and 10,670 shares of Lucid Diagnostics’ Series A-1 Convertible Preferred Stock, par value $0.001 per share (the “ Series A-1 Preferred Stock ”), held by them for 31,790 shares of Series B Prefe
  evidence_url: https://www.sec.gov/Archives/edgar/data/1624326/000149315224009898/0001493152-24-009898-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.